Kailera plans to raise up to $528.5 million through a Nasdaq IPO by offering 33.33 million shares priced $14-$16 each, generating net proceeds of $458.7 million or up to $528.5 million with underwriter options1.
Proceeds will fund development of four GLP-1 obesity assets licensed from Jiangsu Hengrui:
injectable ribupatide ($625M for phase 3 trials through Q2 2028, 18% weight loss in China trial), oral ribupatide ($150M for phase 3 starting Q2 2028, up to 12.1% weight loss), KAI-7535 ($50M for phase 2), and KAI-4729 (phase 1)1.
Company raised $400M Series A in 2024 and $600M Series B in 2025; led by ex-Cerevel CEO Ron Renaud; based in Massachusetts and California1.
IPO details filed with SEC on April 14, 2026, following announcement last month1.
Sources:
1. https://www.fiercebiotech.com/biotech/kailera-shares-details-5285-million-ipo-support-quartet-chinese-obesity-assets